Caption Management’s Protagonist Therapeutics PTGX Stock Holding History

Caption Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-98,934	Closed	-$4.15M	–	1939
2024 Q4	$3.82M	Buy	98,934 +76,834	+348%	+$3.35M	0.04%	463
2024 Q3	$995K	Buy	+22,100	New	+$893K	0.02%	777
2023 Q3	–	Sell	-19,140	Closed	-$529K	–	1494
2023 Q2	$529K	Buy	19,140 +18,897	+7,777%	+$473K	0.01%	810
2023 Q1	$5.59K	Sell	243 -39,757	-99%	-$668K	﹤0.01%	1023
2022 Q4	$436K	Hold	40,000	–	–	0.01%	951
2022 Q3	$337K	Buy	40,000 +29,600	+285%	+$280K	﹤0.01%	1156
2022 Q2	$82K	Sell	10,400 -59,600	-85%	-$721K	﹤0.01%	1312
2022 Q1	$1.66M	Sell	70,000 -122,702	-64%	-$3.46M	0.02%	820
2021 Q4	$6.59M	Buy	192,702 +82,702	+75%	+$2.61M	0.07%	370
2021 Q3	$1.95M	Buy	+110,000	New	+$4.69M	0.02%	769

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Caption Management's PTGX Position: Q1 2025 in Review

Caption Management sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 98,934 shares — an estimated $4.15M sold.

Caption Management first reported a position in PTGX in Q3 2021 and held it in 10 quarters. The position peaked at $6.59M in Q4 2021. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

Caption Management reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
Caption Management sold 98,934 Protagonist Therapeutics shares in Q1 2025, an estimated $4.15M.
Caption Management first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 10 quarters.
Caption Management's Protagonist Therapeutics position peaked at $6.59M in Q4 2021.
275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.